Publication | Open Access

Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis

Rheumatoid DisorderRheumatologyMedicineContinued TreatmentInflammatory Rheumatic DiseasePharmacotherapyInnovator RituximabOncologyNovel TherapyRheumatoid ArthritisRadiology